Soybean Oil
drugOn this page
Also known as Glycine max seed oilIntralipid (fresenius)Liposyn (hospira)Nutrilipid (b braun)Soybean oil component of smoflipidrefined
Summary
Soybean Oil (CHEMBL1201485) is an approved unknown; indicated across 20 conditions including polyp and infertility disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 20 conditions
- Clinical trials: 16
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201485 |
| Name | Soybean Oil |
| Type | Unknown |
| Max phase | 4 |
Also known as: Glycine max seed oil, Intralipid (fresenius), Liposyn (hospira), Nutrilipid (b braun), Soybean oil, Soybean oil component of smoflipid, refined, SOYBEAN OIL
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
20 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| polyp | 3 | MONDO:0005079 | EFO:0000662 |
| infertility disorder | 3 | MONDO:0005047 | EFO:0000545 |
| carcinoma | 3 | MONDO:0004993 | EFO:0000313 |
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
| intestinal disorder | 3 | MONDO:0005020 | EFO:0009431 |
| cholestasis | 3 | MONDO:0001751 | MONDO:0001751 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| acute respiratory distress syndrome | 2 | MONDO:0006502 | EFO:1000637 |
| ischemia reperfusion injury | 2 | MONDO:0005203 | EFO:0002687 |
| metabolic disease | 2 | MONDO:0005066 | EFO:0000589 |
| esophageal atresia | 2 | MONDO:0001044 | HP:0002032 |
| bilirubin encephalopathy | 2 | MONDO:0018477 | EFO:1001002 |
| Alzheimer disease | 2 | MONDO:0004975 | MONDO:0004975 |
| habitual spontaneous abortion | 1 | MONDO:0006774 | EFO:1000954 |
| obesity disorder | 1 | MONDO:0011122 | EFO:0001073 |
| hypertensive disorder | 0 | MONDO:0005044 | EFO:0000537 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 16.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 12 |
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01565278 | PHASE3 | TERMINATED | Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition |
| NCT00644098 | PHASE2 | COMPLETED | Effect of a Soluble Fibre Blend and Medium Chain Triglycerides on Body Composition and Cardiometabolic Risk Factors |
| NCT03742492 | PHASE2 | UNKNOWN | Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects |
| NCT03122912 | PHASE1 | TERMINATED | Explore Effects of Dietary Fish Oil in Human Skin |
| NCT00579540 | Not specified | COMPLETED | Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels |
| NCT01006174 | Not specified | COMPLETED | Dietary Lipids as Primary Modulators of Carotenoid Absorption in Vegetables |
| NCT01250275 | Not specified | COMPLETED | Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease |
| NCT02337231 | Not specified | COMPLETED | Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils |
| NCT02404207 | Not specified | COMPLETED | Soybean Oil Trial of cArdiovascular Risk |
| NCT02599103 | Not specified | COMPLETED | The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects |
| NCT02897674 | Not specified | COMPLETED | Effect of Palm Olein Intake on Lipid Profile and Fat Deposition |
| NCT02924896 | Not specified | COMPLETED | Effect of Palm Olein Intake on Lipid Profile and Appetite Regulation |
| NCT03638661 | Not specified | COMPLETED | n-3 Fatty Acids in Enteral Formula on NK Cell Activity |
| NCT04120220 | Not specified | TERMINATED | Shake It Up: Lipidomics of Lipoproteins and Diet |
| NCT05278910 | Not specified | UNKNOWN | Innovative Methods to Reduce Emissions and Health Impacts of Deep-frying |
| NCT05972798 | Not specified | COMPLETED | Exploration of the Potential Mechanisms of n-3 Fatty Acids Supplementation in Depression and Cognitive Function in Patients With Late-life Depression |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).